Qingfei Paidu decoction, a Chinese herbal medicine against COVID‑19, elevates the blood levels of pro‑inflammatory cytokines: An open‑label, single‑arm pilot study

Qingfei Paidu decoction (QFPD) is a Chinese herbal medicine newly formulated for the treatment of COVID-19. QFPD significantly enhances the therapeutic effects of stan- dard pharmacotherapy in mild to critically ill patients with COVID-19. However, limited information is available on the immunological mechanisms underlying the efficacy of QFPD. In addition, the feasibility of the prophylactic administration of QFPD to uninfected individuals remains unconfirmed. To obtain insight into these issues, an open-label, single-arm pilot study was conducted using 19 healthy uninfected individuals as subjects, and the effects of QFPD ingestion at a dose lower than that recommended for therapeutic use on hematological and immunological parameters were examined. QFPD was prepared according to the Chinese official clinical guideline, except that the dose of each herb was reduced to 1/30 and administered orally to the participants twice daily for 3 days. Low-dose QFPD ingestion significantly increased the plasma levels of pro-inflammatory cytokines, tumor necrosis factor (TNF)-α (P=0.000107), interleukin (IL)-1β (P=0.000982), IL-18 (P=0.00105), IL-2 (P=0.0483) and IL-8 (P=0.000191), key mediators of a broad spectrum of antiviral immunity. No apparent adverse effects were observed during the trial. These findings suggest that the clinical efficacy of QFPD against COVID-19 is, at least in part, associated with its immunological activity to mimic the blood cytokine environ- ment produced by early antiviral immune responses, which are shown to be profoundly suppressed during the early stages of COVID-19. The daily ingestion of low-dose QFPD may thus be a possible option for the prevention of COVID-19 during the epidemic. The present study was prospectively registered at the University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR) under the trial no. UMIN000040341 on May 9, 2020. © 2021 Spandidos Publications. All rights reserved.

[1]  N. Neff,et al.  Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses , 2020, Nature Communications.

[2]  Feng Wu,et al.  Network Pharmacology Analysis to Identify Phytochemicals in Traditional Chinese Medicines That May Regulate ACE2 for the Treatment of COVID-19 , 2020, Evidence-based complementary and alternative medicine : eCAM.

[3]  I. Cavero-Redondo,et al.  Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions , 2020, PloS one.

[4]  You-Wen He,et al.  A Potential Role of Interleukin 10 in COVID-19 Pathogenesis , 2020, Trends in Immunology.

[5]  Linsong Zhang,et al.  Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study , 2020, Pharmacological Research.

[6]  Jiraphun Jittikoon,et al.  Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis , 2020, Journal of Clinical Immunology.

[7]  Fangyue Guo,et al.  Traditional Chinese Medicine as Potential Therapy for COVID-19. , 2020, The American journal of Chinese medicine.

[8]  Weidong Zhang,et al.  Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19 , 2020, Phytomedicine.

[9]  Kai-zheng Zhang,et al.  Network pharmacology suggests biochemical rationale for treating COVID-19 symptoms with a Traditional Chinese Medicine , 2020, Communications Biology.

[10]  J. Schuurs-Hoeijmakers,et al.  Presence of Genetic Variants Among Young Men With Severe COVID-19. , 2020, JAMA.

[11]  E. Kandil,et al.  Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients , 2020, medRxiv.

[12]  Liang Liang,et al.  Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment , 2020, Biomedicine & Pharmacotherapy.

[13]  K. Yung,et al.  Potential Targets for Treatment of Coronavirus Disease 2019 (COVID-19): A Review of Qing-Fei-Pai-Du-Tang and Its Major Herbs. , 2020, The American journal of Chinese medicine.

[14]  J. Knight,et al.  Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease. , 2020, JCI insight.

[15]  Yongkui Wang,et al.  Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming , 2020, Biomedicine & Pharmacotherapy.

[16]  W. Wang,et al.  Viral and host factors related to the clinical outcome of COVID-19 , 2020, Nature.

[17]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[18]  M. Moreno-Eutimio,et al.  Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes , 2020, Microbes and Infection.

[19]  Leyin Zhang,et al.  Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19). , 2020, The American journal of Chinese medicine.

[20]  R. Assaly,et al.  Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis , 2020, Journal of medical virology.

[21]  Tingting Wu,et al.  The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic , 2020, Carbohydrate Polymers.

[22]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[23]  Jun-ling Ren,et al.  Corrigendum to “Traditional Chinese medicine for COVID-19 treatment” [Pharmacol. Res. 155 (2020) 104743] , 2020, Pharmacological Research.

[24]  Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) , 2020, Chinese medical journal.

[25]  Yang Yang,et al.  Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective , 2020, International journal of biological sciences.

[26]  D. Remick.  Interleukin-8. , 2020, Critical care medicine.

[27]  S. Waggoner.  Circadian Rhythms in Immunity , 2020, Current Allergy and Asthma Reports.

[28]  R. Liu,et al.  Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors , 2020, Emerging microbes & infections.

[29]  W. Leonard,et al.  Biology and regulation of IL-2: from molecular mechanisms to human therapy , 2018, Nature Reviews Immunology.

[30]  J. Segura-Egea,et al.  Role of leptin as a link between metabolism and the immune system. , 2017, Cytokine & growth factor reviews.

[31]  Pengpeng Xia,et al.  RNA sensors of the innate immune system and their detection of pathogens , 2017, IUBMB life.

[32]  M. González-Gay,et al.  Leptin in the interplay of inflammation, metabolism and immune system disorders , 2017, Nature Reviews Rheumatology.

[33]  M. Netea,et al.  IL-1β/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections , 2016, PLoS pathogens.

[34]  Nicolas Cermakian,et al.  Circadian Clocks in the Immune System , 2015, Journal of biological rhythms.

[35]  T. Allen,et al.  Interleukin 8 and acute lung injury. , 2014, Archives of pathology & laboratory medicine.

[36]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[37]  Xiangdong Wang,et al.  Role of CCR2 and IL-8 in acute lung injury: a new mechanism and therapeutic target , 2011, Expert review of respiratory medicine.

[38]  Edgar Erdfelder,et al.  G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.